{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:54:17Z","timestamp":1793976857948,"version":"4.8.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In AL amyloidosis complete response (aCR) is defined as negative serum and urine immunofixation with normalized free light chain ratio (FLCR). However, achievement of low levels of involved FLC (iFLC) or difference between iFLC and uninvolved FLC (dFLC) are also relevant endpoints for treatment. We divided 434 consecutive patients with AL amyloidosis into five groups according to response 6 months after treatment initiation: aCR, iFLC &lt;20\u2009mg\/L, normalized-iFLC, dFLC &lt;10\u2009mg\/L, and normalized FLC ratio. Overall survival (OS) was similar (median not reached) in patients in aCR and in those who reached iFLC &lt;20\u2009mg\/L, while it was inferior in all other groups (medians ranging from 79 to 91 months). Time to next therapy or death (TNTD) was longer in subjects attaining aCR (median 69 months) than in subjects reaching any FLC endpoint (medians ranging from 18 to 39 months). The ability of discriminating patients who survived more than 2 years among all responders was greater for current definition of aCR compared to combination of negative serum and urine immunofixation with any low-FLC endpoint. Complete response predicts best outcomes in AL amyloidosis and should be the goal of therapy if tolerability allows.<\/jats:p>","DOI":"10.1038\/s41408-020-00355-6","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T18:35:31Z","timestamp":1598985331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Paolo","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-0499","authenticated-orcid":false,"given":"Marco","family":"Basset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Nuvolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Benigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Rodigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lavatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Foli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"355_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini, G. et al. Systemic immunoglobulin light chain amyloidosis. Nat. Rev. Dis. Primers 4, 38 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"355_CR2","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30, 4541\u20134549 (2012).","journal-title":"J. Clin. Oncol."},{"key":"355_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani, P. et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 130, 625\u201331 (2017).","journal-title":"Blood"},{"key":"355_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich, T. et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 130, 632\u201342 (2017).","journal-title":"Blood"},{"key":"355_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/leu.2017.286","volume":"32","author":"S Sidana","year":"2018","unstructured":"Sidana, S. et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia 32, 729\u201335 (2018).","journal-title":"Leukemia"},{"key":"355_CR6","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani, R. et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 134, 2271\u201380 (2019).","journal-title":"Blood"},{"key":"355_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","volume":"33","author":"E Muchtar","year":"2019","unstructured":"Muchtar, E. et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia 33, 527\u201331 (2019).","journal-title":"Leukemia"},{"key":"355_CR8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/s41375-019-0664-9","volume":"34","author":"S Sidana","year":"2019","unstructured":"Sidana, S. et al. Revisiting complete response in light chain amyloidosis. Leukemia 34, 1472\u20131475 (2019).","journal-title":"Leukemia"},{"key":"355_CR9","doi-asserted-by":"publisher","first-page":"4369a","DOI":"10.1182\/blood-2019-127004","volume":"134","author":"AR Godara","year":"2019","unstructured":"Godara, A. R. et al. In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels <10mg\/L are associated with optimal long-term survival. Blood 134, 4369a (2019).","journal-title":"Blood"},{"key":"355_CR10","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini, G. et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124, 2325\u20132332 (2014).","journal-title":"Blood"},{"key":"355_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","volume":"54","author":"C McCudden","year":"2016","unstructured":"McCudden, C. et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin. Chem. Lab. Med. 54, 1095\u20131104 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"key":"355_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1373\/jalm.2018.026476","volume":"3","author":"KL Thoren","year":"2019","unstructured":"Thoren, K. L., Pianko, M. J., Maakaroun, Y., Landgren, C. O. & Ramanathan, L. V. Distinguishing drug from disease by use of the hydrashift 2\/4 daratumumab assay. J. Appl. Lab. Med. 3, 857\u201363 (2019).","journal-title":"J. Appl. Lab. Med."},{"key":"355_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","volume":"492","author":"LM Moore","year":"2019","unstructured":"Moore, L. M., Cho, S. & Thoren, K. L. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin. Chim. Acta 492, 91\u201394 (2019).","journal-title":"Clin. Chim. Acta"},{"key":"355_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.24772","volume":"92","author":"P Milani","year":"2017","unstructured":"Milani, P. et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am. J. Hematol. 92, 772\u2013779 (2017).","journal-title":"Am. J. Hematol."},{"key":"355_CR15","first-page":"703","volume":"6","author":"P Milani","year":"2018","unstructured":"Milani, P., Merlini, G. & Palladini, G. What does minimal residual disease mean in AL amyloidosis? Expert Opinion on Orphan. Drugs 6, 703\u2013705 (2018).","journal-title":"Drugs"},{"key":"355_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0291-8","volume":"10","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri, A. et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer J. 10, 20 (2020).","journal-title":"Blood Cancer J."},{"key":"355_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E. et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood 129, 82\u201387 (2017).","journal-title":"Blood"},{"key":"355_CR18","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini, G. et al. Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response. Blood 128, 3261 (2016).","journal-title":"Blood"},{"key":"355_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","volume":"4","author":"A Staron","year":"2020","unstructured":"Staron, A. et al. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 4, 880\u2013884 (2020).","journal-title":"Blood Adv."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00355-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:34:15Z","timestamp":1670250855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00355-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00355-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.: speaker honoraria from Pfizer, Janssen-Cilag and travel support from Celgene; M.N.: speaker honoraria from Janssen-Cilag; G.M., consultant: Millennium Pharmaceuticals, Inc., Pfizer, Janssen, Prothena, and IONIS. G.P.: Honoraria and advisory board of Janssen-Cilag, Travel grants from Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"90"}}